Bioseutica sells high-end omega-3 division to German equity firm; major expansion planned


- Last updated on GMT

Bioseutica sells high-end omega-3 division

Related tags Metric system Tonne Omega-3 fatty acid

Swiss nutra and pharma ingredient player Bioseutica has sold 85% of its KD Pharma high-end omega-3 business to German equity firm Capiton. Serious expansion is planned.

Bioseutica did not specify why it had chosen to sell the business at this time but retains a 155 stake and will continue to staff the facility in Bexbach, Germany, although a new manager will be appointed.

Bioseutica VP in business development, Peter Lembke, told us the undisclosed deal would see Capiton invest in the pharma standard plant to significantly expand output of oils.

“Capiton will invest heavily in the capacity expansion of KD,”​ he said.

“The goal is to increase the production capacity up to 2000 metric tonnes per annum  of omega-3 concentrates, which will convert KD Pharma into a global player among high concentrated, omega-3 and API producers.”

“First stage of the expansion will be completed by the end of this year.”

Max capacity

Bioseutica said KD Pharmawas currently running at maximum capacity due to an increase in pharma sector orders.

KD Pharma employs a patented ‘gentle extraction’ supercritical fluid technology called ‘KD pür’ to achieve its purity levels up to 99%.

Bioseutica said further bank financing would be considered for further expansion at the site.


Last year, KD Pharma inked a deal with US microalgal oils firm BioProcess Algae to supply it with ultra-concentrated EPA-rich omega-3 oils for nutraceutical and pharma applications.

"At the moment more than 90% is still from fish oils. However we hope to increase the algae-oil ratio in the near future depending on its availability on the market,"​ Lembke said.

KD Pharma was established in 1988 and originally specialised in separation technologies for the synthetic sugar, lactulose, for the pharma sector.

When that business was sold it shifted its energies to omega-3.

Market consolidation

The high-end omega-3 area has been busy of late with the likes of BASF last year paying €684m for high-end specialist Pronova, in addition to acquiring the Scottish start-up, Equateq (now BASF Callanish).

Lembke acknowledged as much in saying: "There is a lot of consolidation going on presently in the omega-3 market. In order to be able to stay a global leader in highly concentrated omega-3 oils we had to grow our capacity. Capiton gave us the chance to reach this next level."

Capiton manages manages more than €800m in funds spread over 14 medium-sized companies.

Related news

Show more

Related products

show more

Krill oil supports six key areas of healthy aging

Krill oil supports six key areas of healthy aging

Content provided by Aker BioMarine | 23-Feb-2024 | White Paper

The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...

Nootropics Report 2.0: Brain Health Insights

Nootropics Report 2.0: Brain Health Insights

Content provided by dsm-firmenich | 20-Feb-2024 | Insight Guide

The brain health market is constantly growing and evolving, with more consumers looking for innovative ways to support total mind and body wellness.

Sweetening solution for active nutrition

Sweetening solution for active nutrition

Content provided by ADM | 19-Feb-2024 | Case Study

When you add GrainSweet® Liquid Maltodextrin to your active nutrition applications, you get the production efficiencies, clean labels, and clean tastes...

Related suppliers

Follow us


View more